TY - JOUR
T1 - Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations
AU - Carbone, Michele
AU - Pass, Harvey I.
AU - Ak, Guntulu
AU - Alexander, H. Richard
AU - Baas, Paul
AU - Baumann, Francine
AU - Blakely, Andrew M.
AU - Bueno, Raphael
AU - Bzura, Aleksandra
AU - Cardillo, Giuseppe
AU - Churpek, Jane E.
AU - Dianzani, Irma
AU - De Rienzo, Assunta
AU - Emi, Mitsuru
AU - Emri, Salih
AU - Felley-Bosco, Emanuela
AU - Fennell, Dean A.
AU - Flores, Raja M.
AU - Grosso, Federica
AU - Hayward, Nicholas K.
AU - Hesdorffer, Mary
AU - Hoang, Chuong D.
AU - Johansson, Peter A.
AU - Kindler, Hedy L.
AU - Kittaneh, Muaiad
AU - Krausz, Thomas
AU - Mansfield, Aaron
AU - Metintas, Muzaffer
AU - Minaai, Michael
AU - Mutti, Luciano
AU - Nielsen, Maartje
AU - O'Byrne, Kenneth
AU - Opitz, Isabelle
AU - Pastorino, Sandra
AU - Pentimalli, Francesca
AU - de Perrot, Marc
AU - Pritchard, Antonia
AU - Ripley, Robert Taylor
AU - Robinson, Bruce
AU - Rusch, Valerie
AU - Taioli, Emanuela
AU - Takinishi, Yasutaka
AU - Tanji, Mika
AU - Tsao, Anne S.
AU - Tuncer, A. Murat
AU - Walpole, Sebastian
AU - Wolf, Andrea
AU - Yang, Haining
AU - Yoshikawa, Yoshie
AU - Zolondick, Alicia
AU - Schrump, David S.
AU - Hassan, Raffit
N1 - Publisher Copyright:
© 2022 International Association for the Study of Lung Cancer
PY - 2022/7
Y1 - 2022/7
N2 - The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.
AB - The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.
KW - Asbestos
KW - BAP1
KW - Cancer genetics
KW - Germline mutations
KW - Mesothelioma
KW - Tumor predisposition syndromes
UR - http://www.scopus.com/inward/record.url?scp=85130361193&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.03.014
DO - 10.1016/j.jtho.2022.03.014
M3 - Review article
SN - 1556-0864
VL - 17
SP - 873
EP - 889
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 7
ER -